

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

SciVerse ScienceDirect

[www.elsevier.com/locate/brainres](http://www.elsevier.com/locate/brainres)BRAIN  
RESEARCH

## Research Report

# Effects of prenatal stress and monoaminergic perturbations on the expression of serotonin 5-HT<sub>4</sub> and adrenergic $\beta_2$ receptors in the embryonic mouse telencephalon

Angela Chen, Lauren D.S. Kelley, Skirmantas Janušonis\*

Department of Psychological and Brain Sciences, University of California, Santa Barbara, CA 93106-9660, USA

## ARTICLE INFO

## Article history:

Accepted 11 April 2012

Available online 19 April 2012

## Keywords:

Serotonin (5-hydroxytryptamine)

5-HT<sub>4</sub>

Norepinephrine

Brain development

Prenatal risk factors

Nested genes

## ABSTRACT

The serotonin 5-HT<sub>4</sub> receptor (5-HT<sub>4</sub>R) is coded by a complex gene that produces four mRNA splice variants in mice (5-HT<sub>4(a)</sub>R, 5-HT<sub>4(b)</sub>R, 5-HT<sub>4(e)</sub>R, 5-HT<sub>4(f)</sub>R). This receptor has highly dynamic expression in brain development and its splice variants differ in their developmental trajectories. Since 5-HT<sub>4</sub>Rs are important in forebrain function (including forebrain control of serotonergic activity in the brainstem), we investigated the susceptibility of 5-HT<sub>4</sub>R expression in the mouse embryonic telencephalon to prenatal maternal stress and altered serotonin (5-hydroxytryptamine, 5-HT) levels. Because the gene coding the adrenergic  $\beta_2$  receptor ( $\beta_2$ AR) is embedded in the 5-HT<sub>4</sub>R gene, we also investigated whether 5-HT<sub>4</sub>R mRNA levels were modulated by selective  $\beta_2$ AR agents. Timed-pregnant C57BL/6 mice were treated beginning at embryonic day (E) 14 and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was used to assess the mRNA levels of all 5-HT<sub>4</sub>R splice variants and  $\beta_2$ AR in the embryonic telencephalon at E17. Maternal prenatal stress and 5-HT depletion with pCPA, a tryptophan hydroxylase inhibitor, reduced the levels of the 5-HT<sub>4(b)</sub>R splice variant. Terbutaline (a selective  $\beta_2$ AR agonist) and ICI 118,551 (a selective  $\beta_2$ AR antagonist) had no effect on  $\beta_2$ AR and 5-HT<sub>4</sub>R mRNA levels. These results show that prenatal stress and reduced 5-HT levels can alter 5-HT<sub>4</sub>R expression in the developing forebrain and that some 5-HT<sub>4</sub>R splice variants may be more susceptible than others.

© 2012 Elsevier B.V. All rights reserved.

## 1. Introduction

The serotonin (5-hydroxytryptamine, 5-HT) 5-HT<sub>4</sub> receptor (5-HT<sub>4</sub>R) is coded by a complex gene that generates at least ten mRNA splice variants in humans and pigs and four splice variants in mice (5-HT<sub>4(a)</sub>R, 5-HT<sub>4(b)</sub>R, 5-HT<sub>4(e)</sub>R, 5-HT<sub>4(f)</sub>R) (Bockaert et al., 2004, 2006; Claeysen et al., 1999; Ray et al., 2009). The expression of this receptor in mouse and human

brain development is highly dynamic (Lambe et al., 2011; Manzke et al., 2008; Slaten et al., 2010; Waeber et al., 1994, 1996) and, at least in the mouse brain, the 5-HT<sub>4</sub>R splice variants have different developmental trajectories (Hernandez and Janušonis, 2010). This variant-specificity may carry important temporal and spatial information because 5-HT<sub>4</sub>R splice variants differ in their constitutive activity (Claeysen et al., 1999, 2001), internalization properties (Mnie-Filali et al., 2010),

\* Corresponding author at: Department of Psychological and Brain Sciences, University of California, Santa Barbara, CA 93106-9660, USA. Fax: +1 805 893 4303.

E-mail address: [skirmantas.janusonis@psych.ucsb.edu](mailto:skirmantas.janusonis@psych.ucsb.edu) (S. Janušonis).

and association with intracellular proteins (Joubert et al., 2004).

Altered 5-HT<sub>4</sub>R function has been associated with autism spectrum disorders (ASDs) (Vincent et al., 2009), major depressive disorder (Lucas et al., 2007; Rosel et al., 2004), bipolar disorder (Hayden and Nurnberger, 2006), and attention deficit/hyperactivity disorder (Li et al., 2006). A recent study has suggested that 5-HT<sub>4</sub>R is a molecular network hub that controls multiple neural processes (Hu et al., 2011), including those important for the neurobiology of several brain disorders. Different levels of 5-HT<sub>4</sub>R expression have been reported in the amygdala of males and females, which may contribute to sex differences in the prevalence of affective disorders (Madsen et al., 2011).

Evidence suggests that 5-HT<sub>4</sub>R may be a key component in the forebrain control of the brain serotonergic system. Some of this control is mediated by a projection that originates in the medial prefrontal cortex (mPFC) and terminates in the dorsal raphe nucleus (Gabbott et al., 2005; Goncalves et al., 2009; Hajos et al., 1998; Vertes, 2004). In the adult brain, cortical 5-HT<sub>4</sub>Rs modulate the activity of this projection (Bockaert et al., 2011; Lucas et al., 2005) and can alter brain serotonin (5-hydroxytryptamine, 5-HT) levels by affecting raphe serotonergic neurons directly or through GABAergic interneurons (Celada et al., 2001; Jankowski and Sesack, 2004). It has implications for a number of brain disorders, including the biological action of antidepressants (Lucas et al., 2010; Vidal et al., 2009). Since in the embryonic mouse brain young mPFC neurons express 5-HT<sub>4</sub>Rs before they establish synapses with raphe neurons (Slaten et al., 2010), a transient change in 5-HT<sub>4</sub>R expression in the fetal mPFC can potentially result in permanent dysregulation of 5-HT levels in many brain regions.

In the present study, we investigated how maternal prenatal stress and 5-HT depletion affect the mRNA levels of all 5-HT<sub>4</sub>R splice variants in the embryonic mouse telencephalon. Previous studies have shown that maternal stress and serotonergic perturbations can cause various alterations in the developing brain (Altamura et al., 2007; Miyagawa et al., 2011; Peters, 1990; Vitalis et al., 2007). We also investigated whether maternal stress and other environmental signals can affect the 5-HT<sub>4</sub>R expression in the embryonic telencephalon through adrenergic  $\beta_2$  receptors ( $\beta_2$ ARs). Evidence suggests that 5-HT<sub>4</sub>Rs may be functionally associated with  $\beta_2$ ARs, since the  $\beta_2$ AR gene is nested within the 5-HT<sub>4</sub>R gene (Bockaert et al., 2004) and 5-HT<sub>4</sub>Rs can form heterodimers with  $\beta_2$ ARs (Berthouze et al., 2005, 2007). Also, concerns have been raised regarding a possible association between terbutaline (a selective  $\beta_2$ AR agonist used to treat preterm labor) and ASDs (Witter et al., 2009), in which serotonergic abnormalities have long been noted (Anderson, 2002).

## 2. Results


### 2.1. Effects of prenatal stress, $\beta_2$ AR agents, and 5-HT depletion on $\beta_2$ AR mRNA levels

Since the transcription of the 5-HT<sub>4</sub>R gene can potentially be affected by the transcription of the  $\beta_2$ AR gene due to the nested arrangement of the genes (Bockaert et al., 2004; Gibson


et al., 2005), we first investigated whether the  $\beta_2$ AR mRNA amount in the embryonic telencephalon was altered by any of the treatments used in the study (maternal prenatal stress, selective  $\beta_2$ AR agents (terbutaline and ICI 118,551), and 5-HT depletion with pCPA) (Fig. 1). The initial statistical model included these conditions as the fixed effect (Treatment). Adding a random litter effect to the intercept significantly improved the model ( $L=16.8$ ,  $p<0.0001$ ). Allowing each condition to have a different variance did not further improve the model ( $L=4.60$ ,  $df=4$ ,  $p>0.3$ ). The final validated model revealed no significant Treatment effect ( $F_{4,17}=0.65$ ,  $p=0.63$ ). In summary, the analysis indicated the presence of inter-litter variability in the baseline  $\beta_2$ AR mRNA levels (with an estimated standard deviation of 17% of the baseline), but these levels were not significantly altered by any of the used experimental perturbations.

### 2.2. Effects of prenatal stress and $\beta_2$ AR agents on 5-HT<sub>4</sub>R splice variants

We next examined whether maternal restraint stress and a selective  $\beta_2$ AR agonist (terbutaline) affected the mRNA levels of the 5-HT<sub>4</sub>R splice variants in the embryonic telencephalon. We also investigated whether a selective  $\beta_2$ AR antagonist (ICI 118,551), administered prior to restraint stress, attenuated the stress effect on the 5-HT<sub>4</sub>R mRNA levels (Fig. 2). The selective  $\beta_2$ AR agents were included because stress-related signals can act on  $\beta_2$ ARs (Qu et al., 2008),  $\beta_2$ ARs have been shown to form heterodimers with 5-HT<sub>4</sub>Rs (Berthouze et al., 2005, 2007), and the activity of one receptor in a heterodimer can affect the internalization and trafficking of the other receptor, with potential changes in its transcription (Renner et al., in press; Rozenfeld and Devi, 2011).



**Fig. 1 – The normalized  $\beta_2$ AR mRNA amounts in the telencephalon of embryos (E17) from control dams injected with saline (Control) and from dams (i) injected with saline and exposed to maternal prenatal stress (Stress), (ii) injected with a  $\beta_2$ AR antagonist and exposed to maternal prenatal stress (ICI 118,551 + Stress), (iii) injected with a  $\beta_2$ AR agonist (Terbutaline), and (iv) injected with a tryptophan hydroxylase inhibitor (pCPA). The error bars are the standard errors of the means.**



**Fig. 2 – A:** The normalized mRNA amounts of the four 5-HT<sub>4</sub>R splice variants in the telencephalon of embryos (E17) from control dams injected with saline (Control) and from dams (i) injected with saline and exposed to maternal prenatal stress (Stress), (ii) injected with a β<sub>2</sub>AR antagonist and exposed to maternal prenatal stress (ICI 118,551 + Stress), and (iii) injected with a β<sub>2</sub>AR agonist (Terbutaline). **B:** The data obtained by pooling the two treatments with no stress (Control and Terbutaline) and the two treatments with stress (Stress and ICI 118,551 + Stress). The error bars are the standard errors of the means; \**p* < 0.012 (after the Bonferroni correction for the four comparisons (0.05/4)).

The initial statistical model (with Variant, Treatment, and Variant × Treatment as the fixed effects) was significantly improved by allowing each splice variant to have a different variance ( $L=215.8, df=3, p<0.0001$ ) and was further improved by adding correlations (compound symmetry) among all splice variants ( $L=87.7, df=1, p<0.0001$ ). No further improvement was obtained by adding a random litter effect to the intercept ( $L=10^{-7}, p>0.4$ ), suggesting no variability among the litters. The final validated model showed no significant Variant × Treatment interaction ( $F_{9,212}=1.60, p=0.12$ ) and no

Treatment effect in the absence of the interaction term ( $F_{3,221}=0.34, p=0.79$ ).

Since similar differences were observed between stressed and unstressed embryos irrespective of whether or not they had been treated with the selective β<sub>2</sub>AR agents (Fig. 2A), we next combined these data into two groups disregarding the β<sub>2</sub>AR treatment (Fig. 2B). This approach was further supported by the finding that neither the β<sub>2</sub>AR agonist nor the β<sub>2</sub>AR antagonist had a significant effect on the β<sub>2</sub>AR mRNA levels (Fig. 1). Also, the correlations between the β<sub>2</sub>AR mRNA levels and the mRNA levels of each 5-HT<sub>4</sub>R splice variant were not significantly different from zero, in contrast to the strong correlations among the 5-HT<sub>4</sub>R splice variants (Table 1). The two pooled conditions (no stress and stress) produced the same structure of the statistical model (the initial model: Variant, Treatment, Variant × Treatment; different variances for each splice variant:  $L=229.5, df=3, p<0.0001$ ; correlations between the variants:  $L=90.9, df=1, p<0.0001$ ; a random litter effect added to the intercept:  $L=10^{-7}, p>0.4$ ). In the final validated model, the Variant × Treatment interaction was significant ( $F_{3,220}=2.80, p=0.04$ ). There was no Treatment effect in the absence of the interaction ( $F_{1,223}=0.57, p=0.45$ ). Consistent with this finding, only the decrease in the 5-HT<sub>4(b)</sub>R levels was significant after the Bonferroni correction for the four comparisons (5-HT<sub>4(a)</sub>R:  $t_{55}=2.25, p=0.028$ ; 5-HT<sub>4(b)</sub>R:  $t_{55}=2.83, p=0.007$ ; 5-HT<sub>4(e)</sub>R:  $t_{55}=2.55, p=0.014$ ; 5-HT<sub>4(f)</sub>R:  $t_{55}=2.09, p=0.041$ ). The decrease in 5-HT<sub>4(b)</sub>R mRNA was 20%.


**2.3. Effects of 5-HT depletion on 5-HT<sub>4</sub>R splice variants**

We next assessed the susceptibility of all 5-HT<sub>4</sub>R splice variants to low 5-HT levels in the developing brain. Depletion of 5-HT with pCPA strongly reduced the mRNA amount of the 5-HT<sub>4(b)</sub>R splice variant in the embryonic telencephalon, with virtually no effect on the other three 5-HT<sub>4</sub>R splice variants (Fig. 3).

The initial statistical model (with Variant, Treatment, and Variant × Treatment as the fixed effects) was significantly improved by allowing each splice variant to have a different variance ( $L=86.7, df=3, p<0.0001$ ). Adding correlations between all splice variants further improved the model ( $L=27.1, df=1, p<0.0001$ ). Adding a random litter effect to the intercept

**Table 1 – The correlations between the mRNA amounts of the 5-HT<sub>4</sub>R splice variants and β<sub>2</sub>AR at E17 (since correlation measures only association strength, all experimental conditions were used). In each cell, the top number is the Pearson correlation (65 cases) and the bottom number is the *p*-value. By taking into account the Bonferroni correction for the ten cross-correlations, the significance level was set at 0.005 (\*).**

	5-HT <sub>4</sub> R(b)	5-HT <sub>4</sub> R(e)	5-HT <sub>4</sub> R(f)	β <sub>2</sub> -AR
5-HT <sub>4</sub> R(a)	0.579* ( <i>p</i> < 10 <sup>-6</sup> )	0.707* ( <i>p</i> < 10 <sup>-10</sup> )	0.756* ( <i>p</i> < 10 <sup>-12</sup> )	0.059 ( <i>p</i> = 0.64)
5-HT <sub>4</sub> R(b)		0.478* ( <i>p</i> < 10 <sup>-4</sup> )	0.472* ( <i>p</i> < 10 <sup>-4</sup> )	0.061 ( <i>p</i> = 0.63)
5-HT <sub>4</sub> R(e)			0.576* ( <i>p</i> < 10 <sup>-6</sup> )	0.066 ( <i>p</i> = 0.60)
5-HT <sub>4</sub> R(f)				0.067 ( <i>p</i> = 0.59)



**Fig. 3 – The normalized mRNA amounts of the 5-HT<sub>4</sub>R splice variants in the telencephalon of embryos (E17) from control dams and from dams treated with pCPA. The error bars are the standard errors of the means; \* $p < 0.012$  (after the Bonferroni correction for the four comparisons (0.05/4)).**

did not further improve the model ( $L = 0.023$ ,  $p > 0.4$ ), suggesting no significant variability among the litters. The Variant  $\times$  Treatment interaction in the final validated model was highly significant ( $F_{3,92} = 4.65$ ,  $p = 0.0045$ ). The decrease in 5-HT<sub>4(b)</sub>R mRNA was 37% and significant after the Bonferroni correction for the four comparisons ( $t_{23} = 3.14$ ,  $p = 0.005$ ). The Variant  $\times$  Treatment interaction remained significant if the data were analyzed with a mixed-design ANOVA with the Greenhouse–Geisser correction (Field, 2009), to account for the violation of the sphericity assumption ( $F_{1.8,41.4} = 3.72$ ,  $p = 0.037$ ).

### 3. Discussion

The obtained results demonstrate that prenatal stress and reduced 5-HT levels can alter 5-HT<sub>4</sub>R expression in the developing telencephalon and that some 5-HT<sub>4</sub>R splice variants may be more susceptible than others. They also suggest that these effects are not mediated or modulated by  $\beta_2$ AR receptors.

Binding studies in the adult brain have found that altered 5-HT levels typically cause compensatory changes in the availability of 5-HT<sub>4</sub>R to ligands. On the one hand, an increase in 5-HT<sub>4</sub>R binding has been observed in the brains of adult rats and young pigs following 5-HT depletion with pCPA (Ettrup et al., 2011; Licht et al., 2009) and in mice overexpressing the serotonin transporter (5-HTT) (Jennings et al., in press). On the other hand, a decrease in 5-HT<sub>4</sub>R binding has been observed in the adult rat brain following chronic treatment with the selective serotonin reuptake inhibitors fluoxetine and paroxetine (Licht et al., 2009; Vidal

et al., 2009) and in knockout mice lacking 5-HTT (Jennings et al., in press). Prenatal stress can increase 5-HT levels in the embryonic rat brain (Peters, 1990) and it may also increase the number of 5-HT immunoreactive neurons in the adult brains of prenatally exposed mice (Miyagawa et al., 2011). Taken together, these results appear to indicate that prenatal stress is likely to decrease 5-HT<sub>4</sub>R expression in the embryonic telencephalon and that 5-HT depletion is likely to increase it.

Our results are not consistent with these predictions and suggest a more complex developmental mechanism. Both maternal stress and 5-HT depletion caused a decrease in 5-HT<sub>4</sub>R mRNA levels, even though the strength of the effect varied among the conditions and splice variants. These shifts are remarkably similar to the results obtained in another study that has investigated serotonin 5-HT<sub>1A</sub> receptors (5-HT<sub>1A</sub>Rs) in the developing rat brain (Lauder et al., 2000). In this study, prenatal exposure to 5-methoxytryptamine (5-MT), a non-specific 5-HT receptor agonist, has caused a moderate (but significant) decrease in 5-HT<sub>1A</sub>R mRNA levels and prenatal depletion of 5-HT with pCPA has reduced 5-HT<sub>1A</sub>R mRNA levels by nearly 50%. These changes are comparable to our findings not only in their direction, but also in their relative magnitudes (Figs. 2B and 3). Taken together, these findings suggest that, in development, the expression of at least some 5-HT receptors requires an optimal 5-HT level and that a deviation from this optimum may result in a lower number of mRNA transcripts. Abnormally low or high 5-HT levels may induce this change through the same mechanism or two different mechanisms. For example, low 5-HT levels might result in a failure to developmentally upregulate mRNA levels, perhaps in a splice-specific manner (Hernandez and Janušonis, 2010), whereas high 5-HT levels might lead to compensatory downregulation of mRNA levels. Generally, quantitative relationships between mRNA transcripts and receptor availability can be complex or counterintuitive due to the dynamics of the system (Janušonis, 2012). In this regard, several technical considerations are important for the interpretation of our and other related studies.

Most published studies have examined 5-HT<sub>4</sub>R binding, whereas receptor mRNA levels were analyzed in our study and in Lauder et al. (2000). The measures obtained by these two technical approaches are not directly comparable. First, 5-HT<sub>4</sub>R binding can change due to receptor internalization and recycling (Mnie-Filali et al., 2010), with no change in mRNA levels. Second, mRNA analysis cannot detect 5-HT<sub>4</sub>R on the terminals of long-range projections that originate outside the telencephalon. There is strong evidence that 5-HT<sub>4</sub>R can be expressed not only postsynaptically, but also presynaptically in distal axonal segments (Slaten et al., 2010; Vilaro et al., 2005). Third, binding studies cannot distinguish among 5-HT<sub>4</sub>R splice variants; therefore, changes affecting only some of the variants can be masked by other, abundantly expressed variants.

A recent study has shown that early forebrain development depends on maternal 5-HT signals that reach the embryo through the placenta (Bonnin et al., 2011). While no information is currently available about how placental 5-HT synthesis is affected by maternal stress, pCPA is known to inhibit placental 5-HT synthesis (Bonnin et al., 2011). We cannot rule out that placental 5-HT might have contributed to



our findings, but we note that all experimental treatments began at E14, around the time when the mouse forebrain begins to switch to its endogenous 5-HT source, brainstem serotonergic afferents (Bonnin and Levitt, 2011).

The relatively small effect of maternal stress on 5-HT<sub>4</sub>R levels may be due to the restraint length (one hour per day), which was low in comparison to that used in other reports. Daily restraint stress for a total of 1.5–3.0 h is considered standard or “weak” (Darnaudery et al., 2004; Holson et al., 1995; Miyagawa et al., 2011; Ribes et al., 2010; Vallee et al., 1997), and some researchers have used daily six-hour exposures to produce “strong” prenatal stress (Miyagawa et al., 2011). However, such long exposures increase the contribution of various confounding factors, such as muscle fatigue, thermoregulation, blood circulation, and food intake, and may consequently reduce the relevance of the findings to human research. Achieving an optimal balance between experimental effects in rodents and relevance for human research will require a better understanding of the dose-dependent effects of maternal prenatal stress (Mychasiuk et al., 2011).

The susceptibility of the 5-HT<sub>4(b)</sub>R splice variant to altered 5-HT levels is interesting because in the adult brain this variant is readily internalized and recycled (Mnie-Filali et al., 2010). Consequently, it is well-positioned to rapidly respond to fluctuations of 5-HT levels at the protein level and may depend on a relatively stable mRNA pool. If the reduced availability of 5-HT<sub>4(b)</sub>R mRNA persists into adulthood, it may have implications for brain disorders associated with dysfunction of 5-HT homeostasis.

## 4. Experimental procedures

### 4.1. Animals

Timed-pregnant C57BL/6 mice were purchased from Charles River Laboratories and housed individually on a 12:12 light-dark cycle (lights on at 07:00, off at 19:00) with free access to water and food. All procedures have been approved by the UCSB Institutional Animal Care and Use Committee.

### 4.2. Treatment groups

Dams were randomly assigned to one of five treatment groups. In the first (control) group, dams were given an intraperitoneal (i.p.) injection of saline once every day beginning at embryonic day (E) 14. In the second group, embryonic 5-HT was depleted by treating dams with DL-*para*-chlorophenylalanine methyl ester hydrochloride (*p*CPA; Sigma-Aldrich #C3635), a tryptophan hydroxylase inhibitor, dissolved in saline. Based on published reports (Vataeva et al., 2008; Vitalis et al., 2007), dams were given an injection of *p*CPA (200 mg/kg, i.p.) once every day beginning at E14. In the third group, dams were given an intraperitoneal injection of saline and immediately exposed to restraint stress by placing them in a 50 mL polystyrene centrifuge tube with air-holes for 1 h every day beginning at E14. Restraint stress has been used as a controlled stressor in many published studies (Darnaudery et al., 2004; Holson et al., 1995; Jones et al., 2010; Ribes et al., 2010; Vallee et al., 1997). In the fourth group,

dams were exposed to restraint stress as dams in the third group, but instead of saline they were given an injection of ICI 118,551, a selective adrenergic  $\beta_2$  antagonist (Sigma-Aldrich #I127), dissolved in saline. The dose of ICI 118,551 (2 mg/kg, i.p.) was based on published studies (Yalcin et al., 2010; Yu et al., 2010). In the fifth group, dams were treated with terbutaline hemisulfate, a selective adrenergic  $\beta_2$  agonist (Sigma-Aldrich #T2528), dissolved in saline. Based on published reports (Thaker et al., 2006), dams were given an injection of terbutaline (5 mg/kg, i.p.) every day beginning at E14. Both terbutaline and ICI 118,551 could reach the embryonic brain because the mouse blood-brain barrier matures after birth (Daneman et al., 2010) and it is permeable to terbutaline and ICI 118,551 in adulthood (Hsu et al., 1994; Moresco et al., 2000). In all groups, the injected volume was kept constant (0.5 cm<sup>3</sup>).

### 4.3. Tissue collection and RNA isolation

At E17, dams were terminally anesthetized with a mixture of ketamine (200 mg/kg) and xylazine (20 mg/kg), and their uterus was dissected and kept in 0.1 M phosphate-buffered saline (PBS, pH 7.4) on ice. Embryos were removed from the uterus, decapitated, and their brains were dissected with a fine forceps under a stereoscope. The telencephalon was isolated by carefully transecting the telencephalon-diencephalon junction and the total RNA was immediately extracted from the telencephalon with the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer's instructions. The RNA quality (the A260/A280 ratio) and concentration were measured with a NanoDrop spectrophotometer and the samples were stored at –75 °C until further processing. From each sample, an estimated 100 ng of total RNA was reverse-transcribed to cDNA in an Eppendorf Mastercycler pro S using the iScript cDNA Kit (Bio-Rad) according to the manufacturer's instructions. Three embryos were used from each dam.

### 4.4. Quantitative RT-PCR analysis

The quantitative (real-time) reverse-transcription polymerase chain reaction (qRT-PCR) analysis was based on our published protocol (Hernandez and Janušonis, 2010). Five mRNAs of interest (the four 5-HT<sub>4</sub>R splice variants and  $\beta_2$ AR) and three reference (housekeeping) mRNAs ( $\beta_2$ -microglobulin, glyceraldehyde-3-phosphate dehydrogenase, and TATA box binding protein) were analyzed. The amplification was performed in a MyiQ single color real-time PCR detection system (Bio-Rad). Each PCR reaction (20  $\mu$ L) was performed in triplicate and contained the cDNA equivalent of 20 ng RNA, forward and reverse splice variant-specific primers (0.5  $\mu$ M each; Integrated DNA Technologies, Inc.), 0.2 mM dNTPs, 0.25 U Platinum Taq DNA polymerase (Invitrogen), 0.7X SYBR Green I, and 10 nM fluorescein in a PCR buffer containing 10 mM Tris-HCl (pH 9.0 at 25 °C), 50 mM KCl, 2.5 mM MgCl<sub>2</sub>, and 0.1% Triton X-100. The primers were designed in Beacon Designer (Premier Biosoft International) and are given in Table 2. The amplification conditions were as follows: 94 °C (10 min); 45 cycles of 94 °C (10 s), 56 °C (10 s), 72 °C (90 s), 78 °C (20 s), 82 °C (20 s); 95 °C (1 min); and 60 °C (1 min). In order to minimize non-specific signal, fluorescence values used in the analysis were obtained at the highest available temperature at

**Table 2 – The quantitative RT-PCR primers and the amplification efficiencies (since amplification efficiencies depend only on primers and amplification conditions, all experimental conditions were used to obtain the estimates). Abbreviations: bp, amplicon length in base pairs; T, product analysis temperature; E, mean amplification efficiency; SEM, standard error of the mean.**

Target mRNA accession	Target mRNA	Forward primer (5'-3')	Reverse primer (5'-3')	bp	T (°C)	E ± SEM
Y09587	5-HT <sub>4</sub> R(a)	ATCCTCTGCTGTGATGATGAG	ACTGTGCAAAAACGTATACCTTTAG	120	82	1.696 ± 0.006
Y09585	5-HT <sub>4</sub> R(b)	CCTGGACAATGACCTAGAAGAC	TTGCCTGTGCTCTTGGAAAG	121	82	1.734 ± 0.006
Y09588	5-HT <sub>4</sub> R(e)	ATCCTCTGCTGTGATGATGAG	GGAACAGGTCTATTGGGAAAG	134	82	1.713 ± 0.005
AJ011369	5-HT <sub>4</sub> R(f)	ACCTGTTCCCGTCTAACTGAG	TAGTAACCTGTTCATGCGAGACAC	190	82	1.766 ± 0.005
NM_007420	β <sub>2</sub> AR	TCTGTCTGTCTCTGTGGATGATG	CCCATTGTCACAGCAGAAAAGG	167	78	1.731 ± 0.005
NM_009735 (reference gene)	β <sub>2</sub> -Microglobulin (B2M)	GGAAATGGGAAGCCGCAACATAC	AGAAAGACCAGTCTTGTGTAAG	143	78	1.812 ± 0.005
NM_008084 (reference gene)	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)	AATGTGTCCGTCGTGGATCTGA	AGTGTAGCCCCAAGATGCCCTTC	117	82	1.794 ± 0.005
NM_013684 (reference gene)	TATA box binding protein (TBP)	GTTGGTGATTGTTGGTTTAAGGG	GGAAGCGGGAATGTATCTGG	197	78	1.801 ± 0.005

which no melting of the product double-stranded DNA was detected. Controls with no reverse transcription indicated no contamination with genomic DNA.

The efficiency of each amplification was calculated automatically by using a Mathematica (Wolfram Research, Inc.) program (Hernandez and Janušonis, 2010) based on a published algorithm (Tichopad et al., 2003) with modifications. Briefly, linear regression was used to model the initial baseline of the non-transformed fluorescence data, and the beginning of the exponential phase was defined as the amplification cycle in which the first of three consecutive regression outliers was detected (the outliers were defined as points whose externally studentized residual was significant at the 0.005 level). The exponential phase was modeled by linear regression of the log-transformed fluorescence data and the end of the exponential phase was defined as the amplification cycle in which the first regression outlier was detected (the outlier was defined as the first point whose externally studentized residual was significant at the 0.10 level). The mRNA amount in the initial tissue sample was calculated as the triplicate mean of  $(RFU - baseline)E^{-x}$ , where *baseline* is the mean baseline fluorescence before the exponential phase, *x* and *RFU* are the cycle number and the fluorescence at the mid-point of the exponential phase, and *E* is the amplification efficiency of the mRNA species. The normalized mRNA amount was calculated by dividing the mRNA amount by the geometric mean of the mRNA amounts of the reference genes in the same sample (Vandesompele et al., 2002). For convenience, the obtained value was multiplied by 1000.

#### 4.5. Statistical analysis

Statistical analyses were performed in R 2.14 (The R Foundation for Statistical Computing) and in IBM SPSS 19 (IBM, Inc.). Mixed-effects models were analyzed with the R *nlme* package (Pinheiro et al., 2011) and non-homogeneity of variances was accounted for by choosing the *varIdent* variance structure (Zuur et al., 2009). These approaches are superior to traditional statistical tests that are based on mathematical convenience rather than biological relevance and are strongly recommended for experimental research in neuroscience (Lazic, 2010; Nakagawa and Hauber, 2011). By following a well-established procedure (Zuur et al., 2009), statistical models were built sequentially by using restricted maximum likelihood estimation (REML) and maximum likelihood estimation (ML): (i) first, a “beyond optimal” model was constructed that included all relevant fixed effects; (ii) the structure of variances and random effects was optimized by comparing nested REML-fitted models with ANOVA and testing the significance of the likelihood ratios (*L*) (in mixed-effects analyses, the significance of *L* was calculated “on the boundary”); (iii) the structure of fixed effects was optimized by comparing nested ML-fitted models with ANOVA and testing the significance of *L* (the non-significant fixed effects were removed); (iv) the final model was refitted with REML and validated (tested for the normality and homogeneity of residuals). In all tests, the significance level was set at 0.05. For post-hoc analyses, the Bonferroni correction was used.

## Acknowledgments

This work was supported by a Hellman Family Faculty Fellowship (SJ) and UCSB Academic Senate grants. We thank Watita Tamavimok for technical assistance.

## REFERENCES

- Altamura, C., Dell'Acqua, M.L., Moessner, R., Murphy, D.L., Lesch, K.P., Persico, A.M., 2007. Altered neocortical cell density and layer thickness in serotonin transporter knockout mice: a quantitation study. *Cereb. Cortex* 17, 1394–1401.
- Anderson, G.M., 2002. Genetics of childhood disorders: XLV. Autism, part 4: serotonin in autism. *J. Am. Acad. Child Adolesc. Psychiatry* 41, 1513–1516.
- Berthouze, M., Ayoub, M., Russo, O., Rivail, L., Sicsic, S., Fischmeister, R., Berque-Bestel, I., Jockers, R., Lezoualc'h, F., 2005. Constitutive dimerization of human serotonin 5-HT<sub>4</sub> receptors in living cells. *FEBS Lett.* 579, 2973–2980.
- Berthouze, M., Rivail, L., Lucas, A., Ayoub, M.A., Russo, O., Sicsic, S., Fischmeister, R., Berque-Bestel, I., Jockers, R., Lezoualc'h, F., 2007. Two transmembrane Cys residues are involved in 5-HT<sub>4</sub> receptor dimerization. *Biochem. Biophys. Res. Commun.* 356, 642–647.
- Bockaert, J., Claeysen, S., Compan, V., Dumuis, A., 2004. 5-HT<sub>4</sub> receptors. *Curr. Drug Targets CNS Neurol. Disord.* 3, 39–51.
- Bockaert, J., Claeysen, S., Becamel, C., Dumuis, A., Marin, P., 2006. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. *Cell Tissue Res.* 326, 553–572.
- Bockaert, J., Claeysen, S., Compan, V., Dumuis, A., 2011. 5-HT<sub>4</sub> receptors, a place in the sun: act two. *Curr. Opin. Pharmacol.* 11, 87–93.
- Bonnin, A., Levitt, P., 2011. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. *Neuroscience* 197, 1–7.
- Bonnin, A., Goeden, N., Chen, K., Wilson, M.L., King, J., Shih, J.C., Blakely, R.D., Deneris, E.S., Levitt, P., 2011. A transient placental source of serotonin for the fetal forebrain. *Nature* 472, 347–350.
- Celada, P., Puig, M.V., Casanovas, J.M., Guillazo, G., Artigas, F., 2001. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A. GABA<sub>A</sub>, and glutamate receptors. *J. Neurosci.* 21, 9917–9929.
- Claeysen, S., Sebben, M., Becamel, C., Bockaert, J., Dumuis, A., 1999. Novel brain-specific 5-HT<sub>4</sub> receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. *Mol. Pharmacol.* 55, 910–920.
- Claeysen, S., Sebben, M., Becamel, C., Parmentier, M.L., Dumuis, A., Bockaert, J., 2001. Constitutively active mutants of 5-HT<sub>4</sub> receptors are they in unique active states? *EMBO Rep.* 2, 61–67.
- Daneman, R., Zhou, L., Agalliu, D., Cahoy, J.D., Kaushal, A., Barres, B.A., 2010. The mouse blood–brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. *PLoS One* 5, e13741.
- Darnaudery, M., Dutriez, I., Viltart, O., Morley-Fletcher, S., Maccari, S., 2004. Stress during gestation induces lasting effects on emotional reactivity of the dam rat. *Behav. Brain Res.* 153, 211–216.
- Ettrup, A., Kornum, B.R., Weikop, P., Knudsen, G.M., 2011. An approach for serotonin depletion in pigs: effects on serotonin receptor binding. *Synapse* 65, 136–145.
- Field, A., 2009. *Discovering Statistics Using SPSS*, third ed. SAGE, Los Angeles.
- Gabbott, P.L., Warner, T.A., Jays, P.R., Salway, P., Busby, S.J., 2005. Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic centers. *J. Comp. Neurol.* 492, 145–177.
- Gibson, C.W., Thomson, N.H., Abrams, W.R., Kirkham, J., 2005. Nested genes: biological implications and use of AFM for analysis. *Gene* 350, 15–23.
- Goncalves, L., Nogueira, M.I., Shammah-Lagnado, S.J., Metzger, M., 2009. Prefrontal afferents to the dorsal raphe nucleus in the rat. *Brain Res. Bull.* 78, 240–247.
- Hajos, M., Richards, C.D., Szekely, A.D., Sharp, T., 1998. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. *Neuroscience* 87, 95–108.
- Hayden, E.P., Nurnberger Jr., J.I., 2006. Molecular genetics of bipolar disorder. *Genes Brain Behav.* 5, 85–95.
- Hernandez, M.C., Janušonis, S., 2010. Quantitative mRNA analysis of serotonin 5-HT<sub>4</sub> and adrenergic  $\beta_2$  receptors in the mouse embryonic telencephalon. *Dev. Neurosci.* 32, 278–287.
- Holson, R.R., Gough, B., Sullivan, P., Badger, T., Sheehan, D.M., 1995. Prenatal dexamethasone or stress but not ACTH or corticosterone alter sexual behavior in male rats. *Neurotoxicol. Teratol.* 17, 393–401.
- Hsu, C.H., Robinson, C.P., Basmadjian, G.P., 1994. Tissue distribution of <sup>3</sup>H-terbutaline in rabbits. *Life Sci.* 54, 1465–1469.
- Hu, V.W., Addington, A., Hyman, A., 2011. Novel autism subtype-dependent genetic variants are revealed by quantitative trait and subphenotype association analyses of published GWAS data. *PLoS One* 6, e19067.
- Jankowski, M.P., Sesack, S.R., 2004. Prefrontal cortical projections to the rat dorsal raphe nucleus: ultrastructural features and associations with serotonin and gamma-aminobutyric acid neurons. *J. Comp. Neurol.* 468, 518–529.
- Janušonis, S., 2012. Interaction with no correlation: An experimental pitfall in neural systems. *J. Neurosci. Meth.* 206, 151–157.
- Jennings, K.A., Licht, C.L., Bruce, A., Lesch, K.P., Knudsen, G.M., Sharp, T., in press. Genetic variation in 5-hydroxytryptamine transporter expression causes adaptive changes in 5-HT<sub>4</sub> receptor levels. *Int. J. Neuropsychopharmacol.*
- Jones, K.L., Smith, R.M., Edwards, K.S., Givens, B., Tilley, M.R., Beversdorf, D.Q., 2010. Combined effect of maternal serotonin transporter genotype and prenatal stress in modulating offspring social interaction. *Int. J. Dev. Neurosci.* 28, 529–536.
- Joubert, L., Hanson, B., Barthet, G., Sebben, M., Claeysen, S., Hong, W., Marin, P., Dumuis, A., Bockaert, J., 2004. New sorting nexin (SNX27) and NHERF specifically interact with the 5-HT<sub>4a</sub> receptor splice variant: roles in receptor targeting. *J. Cell Sci.* 117, 5367–5379.
- Lambe, E.K., Fillman, S.G., Webster, M.J., Weickert, C.S., 2011. Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development. *PLoS One* 6, e22799.
- Lauder, J.M., Liu, J., Grayson, D.R., 2000. In utero exposure to serotonergic drugs alters neonatal expression of 5-HT<sub>1A</sub> receptor transcripts: a quantitative RT-PCR study. *Int. J. Dev. Neurosci.* 18, 171–176.
- Lazic, S.E., 2010. The problem of pseudoreplication in neuroscientific studies: is it affecting your analysis? *BMC Neurosci.* 11, 5.
- Li, J., Wang, Y., Zhou, R., Wang, B., Zhang, H., Yang, L., Faraone, S.V., 2006. Association of attention-deficit/hyperactivity disorder with serotonin 4 receptor gene polymorphisms in Han Chinese subjects. *Neurosci. Lett.* 401, 6–9.
- Licht, C.L., Marcussen, A.B., Wegener, G., Overstreet, D.H., Aznar, S., Knudsen, G.M., 2009. The brain 5-HT<sub>4</sub> receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration. *J. Neurochem.* 109, 1363–1374.
- Lucas, G., Compan, V., Charnay, Y., Neve, R.L., Nestler, E.J., Bockaert, J., Barrot, M., Debonnel, G., 2005. Frontocortical 5-HT<sub>4</sub> receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT(4) agonists. *Biol. Psychiatry* 57, 918–925.



- Lucas, G., Rymar, V.V., Du, J., Mnie-Filali, O., Bisgaard, C., Manta, S., Lambas-Senas, L., Wiborg, O., Haddjeri, N., Pineyro, G., Sadikot, A.F., Debonnel, G., 2007. Serotonin(4) (5-HT<sub>4</sub>) receptor agonists are putative antidepressants with a rapid onset of action. *Neuron* 55, 712–725.
- Lucas, G., Du, J., Romeas, T., Mnie-Filali, O., Haddjeri, N., Pineyro, G., Debonnel, G., 2010. Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin<sub>4</sub> receptor agonists in the rat. *PLoS One* 5, e9253.
- Madsen, K., Haahr, M.T., Marnier, L., Keller, S.H., Baare, W.F., Svare, C., Hasselbalch, S.G., Knudsen, G.M., 2011. Age and sex effects on 5-HT<sub>4</sub> receptors in the human brain: a [<sup>11</sup>C] SB207145 PET study. *J. Cereb. Blood Flow Metab.* 31, 1475–1481.
- Manzke, T., Preusse, S., Hulsman, S., Richter, D.W., 2008. Developmental changes of serotonin 4(a) receptor expression in the rat pre-Botzinger complex. *J. Comp. Neurol.* 506, 775–790.
- Miyagawa, K., Tsuji, M., Fujimori, K., Saito, Y., Takeda, H., 2011. Prenatal stress induces anxiety-like behavior together with the disruption of central serotonin neurons in mice. *Neurosci. Res.* 70, 111–117.
- Mnie-Filali, O., Amraei, M.G., Benmbarek, S., Archer-Lahlou, E., Penas-Cazorla, R., Vilaro, M.T., Boye, S.M., Pineyro, G., 2010. Serotonin 4 receptor (5-HT<sub>4</sub>R) internalization is isoform-specific: effects of 5-HT and RS67333 on isoforms A and B. *Cell. Signal.* 22, 501–509.
- Moresco, R.M., Matarrese, M., Soloviev, D., Simonelli, P., Rigamonti, M., Gobbo, C., Todde, S., Carpinelli, A., Kienle, M.G., Fazio, F., 2000. Synthesis and in vivo evaluation of [<sup>11</sup>C]ICI 118551 as a putative subtype selective  $\beta_2$ -adrenergic radioligand. *Int. J. Pharm.* 204, 101–109.
- Mychasiuk, R., Ilnytskyi, S., Kovalchuk, O., Kolb, B., Gibb, R., 2011. Intensity matters: brain, behaviour and the epigenome of prenatally stressed rats. *Neuroscience* 180, 105–110.
- Nakagawa, S., Hauber, M.E., 2011. Great challenges with few subjects: statistical strategies for neuroscientists. *Neurosci. Biobehav. Rev.* 35, 462–473.
- Peters, D.A., 1990. Maternal stress increases fetal brain and neonatal cerebral cortex 5-hydroxytryptamine synthesis in rats: a possible mechanism by which stress influences brain development. *Pharmacol. Biochem. Behav.* 35, 943–947.
- Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D., 2011. nlme: Linear and Nonlinear Mixed Effects Models. R Foundation for Statistical Computing 3.1. .
- Qu, L.-L., Guo, N.-N., Li, B.-M., 2008.  $\beta_1$ - and  $\beta_2$ -Adrenoreceptors in basolateral nucleus of amygdala and their roles in consolidation of fear memory in rats. *Hippocampus* 18, 1131–1139.
- Ray, A.M., Kelsell, R.E., Houp, J.A., Kelly, F.M., Medhurst, A.D., Cox, H.M., Calver, A.R., 2009. Identification of a novel 5-HT<sub>4</sub> receptor splice variant (r5-HT<sub>4c1</sub>) and preliminary characterisation of specific 5-HT<sub>4a</sub> and 5-HT<sub>4b</sub> receptor antibodies. *Eur. J. Pharmacol.* 604, 1–11.
- Renner U., Zeug A., Woehler A., Niebert M., Dityatev A., Dityateva G., Gorinski N., Guseva D., Abdel-Galil D., Fröhlich M., Döring F., Wischmeyer E., Richter D.W., Neher E., Ponimaskin E.G., in press. Heterodimerization of serotonin receptors 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> differentially regulates receptor signalling and trafficking. *J. Cell Sci.*
- Ribes, D., Fuentes, S., Torrente, M., Colomina, M.T., Domingo, J.L., 2010. Combined effects of perfluorooctane sulfonate (PFOS) and maternal restraint stress on hypothalamus adrenal axis (HPA) function in the offspring of mice. *Toxicol. Appl. Pharmacol.* 243, 13–18.
- Rosel, P., Arranz, B., Urrutavizcaya, M., Oros, M., San, L., Navarro, M.A., 2004. Altered 5-HT<sub>2A</sub> and 5-HT<sub>4</sub> postsynaptic receptors and their intracellular signalling systems IP<sub>3</sub> and cAMP in brains from depressed violent suicide victims. *Neuropsychobiology* 49, 189–195.
- Rozenfeld, R., Devi, L.A., 2011. Exploring a role for heteromerization in GPCR signalling specificity. *Biochem. J.* 433, 11–18.
- Slaten, E.R., Hernandez, M.C., Albay III, R., Lavian, R., Janušonis, S., 2010. Transient expression of serotonin 5-HT<sub>4</sub> receptors in the mouse developing thalamocortical projections. *Dev. Neurobiol.* 70, 165–181.
- Thaker, P.H., Han, L.Y., Kamat, A.A., Arevalo, J.M., Takahashi, R., Lu, C., Jennings, N.B., Armaiz-Pena, G., Bankson, J.A., Ravoori, M., Merritt, W.M., Lin, Y.G., Mangala, L.S., Kim, T.J., Coleman, R.L., Landen, C.N., Li, Y., Felix, E., Sanguino, A.M., Newman, R.A., Lloyd, M., Gershenson, D.M., Kundra, V., Lopez-Berestein, G., Lutgendorf, S.K., Cole, S.W., Sood, A.K., 2006. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. *Nat. Med.* 12, 939–944.
- Tichopad, A., Dilger, M., Schwarz, G., Pfaffl, M.W., 2003. Standardized determination of real-time PCR efficiency from a single reaction set-up. *Nucleic Acids Res.* 31, e122.
- Vallee, M., Mayo, W., Dellu, F., Le, M.M., Simon, H., Maccari, S., 1997. Prenatal stress induces high anxiety and postnatal handling induces low anxiety in adult offspring: correlation with stress-induced corticosterone secretion. *J. Neurosci.* 17, 2626–2636.
- Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman, F., 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.* 3 RESEARCH0034.
- Vataeva, L.A., Kudrin, V.S., Vershinina, E.A., Mosin, V.M., Tiul'kova, E.I., Otellin, V.A., 2008. Maternal para-chlorophenylalanine exposure modifies central monoamines and behaviors in the adult offspring. *Brain Res.* 1234, 1–7.
- Vertes, R.P., 2004. Differential projections of the infralimbic and prelimbic cortex in the rat. *Synapse* 51, 32–58.
- Vidal, R., Valdizan, E.M., Mostany, R., Pazos, A., Castro, E., 2009. Long-term treatment with fluoxetine induces desensitization of 5-HT<sub>4</sub> receptor-dependent signalling and functionality in rat brain. *J. Neurochem.* 110, 1120–1127.
- Vilaro, M.T., Cortes, R., Mengod, G., 2005. Serotonin 5-HT<sub>4</sub> receptors and their mRNAs in rat and guinea pig brain: distribution and effects of neurotoxic lesions. *J. Comp. Neurol.* 484, 418–439.
- Vincent, J.B., Noor, A., Windpassinger, C., Gianakopoulos, P.J., Schwarzbraun, T., Alfred, S.E., Stachowiak, B., Scherer, S.W., Roberts, W., Wagner, K., Kroisel, P.M., Petek, E., 2009. Characterization of a de novo translocation t(5;18)(q33.1;q12.1) in an autistic boy identifies a breakpoint close to SH3TC2, ADRB2, and HTR4 on 5q, and within the desmocolin gene cluster on 18q. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 150B, 817–826.
- Vitalis, T., Cases, O., Passemard, S., Callebert, J., Parnavelas, J.G., 2007. Embryonic depletion of serotonin affects cortical development. *Eur. J. Neurosci.* 26, 331–344.
- Waeber, C., Sebben, M., Nieouillon, A., Bockaert, J., Dumuis, A., 1994. Regional distribution and ontogeny of 5-HT<sub>4</sub> binding sites in rodent brain. *Neuropharmacology* 33, 527–541.
- Waeber, C., Sebben, M., Bockaert, J., Dumuis, A., 1996. Regional distribution and ontogeny of 5-HT<sub>4</sub> binding sites in rat brain. *Behav. Brain Res.* 73, 259–262.
- Witter, F.R., Zimmerman, A.W., Reichmann, J.P., Connors, S.L., 2009. In utero  $\beta_2$  adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. *Am. J. Obstet. Gynecol.* 201, 553–559.
- Yalcin, I., Tessier, L.H., Petit-Demouliere, N., Waltisperger, E., Hein, L., Freund-Mercier, M.J., Barrot, M., 2010. Chronic treatment with agonists of  $\beta_2$ -adrenergic receptors in neuropathic pain. *Exp. Neurol.* 221, 115–121.
- Yu, N.N., Wang, X.X., Yu, J.T., Wang, N.D., Lu, R.C., Miao, D., Tian, Y., Tan, L., 2010. Blocking  $\beta_2$ -adrenergic receptor attenuates acute stress-induced amyloid  $\beta$  peptides production. *Brain Res.* 1317, 305–310.
- Zuur, A.F., Ieno, E.N., Walker, N.J., Saveliev, A.A., Smith, G.M., 2009. *Mixed Effects Models and Extensions in Ecology with R*. Springer, New York.